Cambridge-based AI drug turnaround company Ignota Labs has acquired the full clinical asset portfolio of former unicorn Kronos. The once high-flying MedTech, which was listed on the Nasdaq Stock Exchange, saw its valuation peak at $3.5 billion before its collapse earlier this year. Kronos had advanced two key programmes – istisociclib, a CDK9 inhibitor, and … Continue reading Former $3.5bn-valued Kronos has assets acquired by Ignota Labs